

<p>Study Title:</p>	<p>A Phase 1/2 Open-Label, Multicenter Study Evaluating the Safety and Efficacy of KITE-363 or KITE-753, Autologous Anti-CD19/CD20 CAR T-cell Therapies, in Subjects with Relapsed and/or Refractory B-cell Lymphoma</p>
<p>Indication:</p>	<p>Relapsed and/or refractory (r/r) B-cell lymphoma</p>
<p>Investigational Product:</p>	<p>KITE-363 (an autologous anti-CD19/CD20 chimeric antigen receptor [CAR] T-cell product)</p> <p>KITE-753 (a rapidly manufactured version of KITE-363 [an autologous anti-CD19/CD20 CAR T-cell product])</p>
<p>Study Design:</p>	<p><b><u>Phase 1</u></b></p> <p>The Phase 1 portion of the study is an open-label, multicenter study evaluating the safety and efficacy of KITE-363 or KITE-753 in subjects with r/r B-cell lymphoma. Assignment to the KITE-363 or KITE-753 arm of the study will be managed by the Sponsor. The study will comprise dose-escalation (Phase 1a) and dose-expansion (Phase 1b) for each study arm.</p> <p><b><u>Phase 1a: Dose-Escalation</u></b></p> <p>The dose-escalation portion of the study will use a 3 + 3 study design. Subjects with r/r LBCL; including all subtypes per World Health Organization [WHO] 2022 {Alaggio 2022} as well as transformed indolent non-Hodgkin lymphoma [iNHL], r/r follicular lymphoma (FL), r/r marginal zone lymphoma (MZL), r/r nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL), or r/r mediastinal gray zone lymphoma (MGZL) will be enrolled and treated with KITE-363 or KITE-753 at the sequential dose-escalation levels and evaluated for DLTs. Additional disease types may be considered based on feedback from participating investigators and in discussion with the safety review team (SRT).</p> <p><b>KITE-363</b></p> <p>There will be 5 planned dose-escalation levels.</p> <p><b>KITE-753</b></p> <p>There will be 3 planned dose-escalation levels as part of the Phase 1a dose-escalation portion of the study for KITE-753, which is being conducted independently of the dose-escalation of KITE-363.</p> <p><b><u>Phase 1b: Dose-Expansion</u></b></p> <p>To further characterize the benefits/risks of treatment with KITE-363 or KITE-753, the sponsor may, in consultation with the SRT, choose to treat additional subjects at 1 or more dose-escalation level cohorts within each study arm (referred to as dose-expansion cohorts). Within the dose-expansion cohorts, subjects with r/r LBCL will be placed into 2 separate subgroups: CAR-T therapy naïve (Cohort A) and CAR-T therapy exposed (Cohort B).</p> <p>Separate dose-expansion cohorts may be explored for treatment with KITE-753 only for subjects with:</p> <ul style="list-style-type: none"> <li>• Frontline LBCL (Cohort C)</li> <li>• r/r mantle cell lymphoma (MCL; Cohort D)</li> </ul> <p><b><u>Phase 2</u></b></p> <p>The Phase 2 portion of the study is an open-label, multicenter, single-arm study evaluating the safety and efficacy of KITE-753 in subjects with r/r LBCL who have received at least 2 prior lines of systemic therapy.</p>